We have developed a novel aptamer–siRNA-based therapy, targeting liver metastatic PDAC and HCC, which leverages overexpression of TfR for cancer cell delivery and the critical role of the transcription factor C/EBPβ in tumor development. Here, TFRC is linked to hepatocellular carcinoma.